Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stockStrides Pharma Science Ltd (STAR) is currently trading at 1,050.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Strides Pharma Science Limited is a global pharmaceutical company based in Bengaluru, India. It focuses on manufacturing and exporting a wide range of generic and branded pharmaceutical products. In Q3FY26, the company achieved its highest ever EBITDA of ₹2,359 million, reflecting a 12.2% year-over-year increase, demonstrating strong operational performance. Despite a modest revenue growth of 3.6%, the company saw an exceptional 38.6% increase in operational PAT, driven by strong performance in Ex-US markets, which grew by 20% YoY. The Ex-US markets are becoming increasingly significant, now contributing to 47% of revenue, indicating a strategic shift in the company’s geographical revenue distribution. Strides Pharma's balance sheet has strengthened, with a reduction in net debt due to effective cash flow management and a focus on high-margin products.
Over the past 52 weeks, Strides Pharma Science Ltd has traded between a low of ₹769.60 and a high of ₹1,231.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Strides Pharma Science Ltd has a market capitalization of approximately 9,622.83. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Strides Pharma Science Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 17.30 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 9,622.83 Cr, Strides Pharma Science Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Strides Pharma Science Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Strides Pharma Science Ltd is 17.30. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
FY26 consolidated revenue was ₹48,587 million, up 6.4% year-on-year. The company said underlying growth excluding access markets was about 10%.
FY25 U.S. revenue was ₹24,457 million (US$291 million), up 21.8% year on year from ₹20,078 million (US$243 million) in FY24.
Strides Pharma reported consolidated net profit of ₹129.28 crore for Q4FY26, up 51% year-on-year, according to its regulatory filing.
Strides reported consolidated net profit of ₹129.28 crore for Q4 FY26 in a regulatory filing; another report cited ₹126.94 crore for the same quarter.
Bearish
3
Neutral
7
Bullish
4
Bearish
18
Neutral
7
Bullish
21
Bearish
15
Neutral
0
Bullish
17
Strides Pharma Science Limited is a global pharmaceutical company based in Bengaluru, India. It focuses on manufacturing and exporting a wide range of generic and branded pharmaceutical products.
In Q3FY26, the company achieved its highest ever EBITDA of ₹2,359 million, reflecting a 12.2% year-over-year increase, demonstrating strong operational performance.
Despite a modest revenue growth of 3.6%, the company saw an exceptional 38.6% increase in operational PAT, driven by strong performance in Ex-US markets, which grew by 20% YoY.
The Ex-US markets are becoming increasingly significant, now contributing to 47% of revenue, indicating a strategic shift in the company’s geographical revenue distribution.
Strides Pharma's balance sheet has strengthened, with a reduction in net debt due to effective cash flow management and a focus on high-margin products.
Pharmaceuticals & Biotechnology
Pharmaceuticals
9,682 Cr
Low Risk
17.4
37.2
0.6
3.1
1,231.45
769.60
Sales CAGR
Profit CAGR
ROE
ROCE
Earnings Call/Transcript
Strides Pharma Science Ltd scheduled an earnings call on July 31, 2026 at 17:00 IST to discuss unaudited results for quarter ended June 30, 2026; senior management to participate and registration details provided.
Earnings Call/Transcript
Strides Pharma Science Ltd scheduled an earnings conference call on July 31, 2026 at 17:00 IST to discuss unaudited results for the quarter ended June 30, 2026; preregistration and dial-in details provided.
Board Meeting
Strides Pharma Science Ltd will hold a Board meeting on 2026-07-31 to consider and approve unaudited standalone and consolidated results for quarter ended 2026-06-30; trading window closed from 2026-07-01.
Board Meeting
Strides Pharma Science Ltd: Board will meet on 2026-07-31 to consider and approve unaudited standalone and consolidated financial results for quarter ended 2026-06-30; trading window closed from 2026-07-01.
Regulatory/Compliance Filing
Strides Pharma Science Ltd filed its Business Responsibility & Sustainability Report (BRSR) for FY 2025-26 with BSE and NSE on July 21, 2026.
Regulatory/Compliance Filing
Strides Pharma Science Ltd submitted its Business Responsibility & Sustainability Report (BRSR) for the financial year ended March 31, 2026, to BSE and NSE on July 21, 2026.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
6780.50 | 11,257 Cr | 34.43 | 21.46 | 6.12 | 62.32 | 84.14 | 38.86 | ||
576.55 | 10,906 Cr | 44.01 | 5.05 | 0.19 | 18.22 | 24.16 | 15.10 | ||
4671.45 | 10,773 Cr | 41.77 | 28.05 | 1.60 | 62.53 | 75.60 | 47.15 | ||
676.00 | 10,638 Cr | 41.69 | 3.21 | 0.43 | 7.70 | 10.95 | 4.71 | ||
868.00 | 9,676 Cr | 55.96 | 10.95 | 0.00 | 19.57 | 22.16 | 14.83 | ||
1045.20 | 9,623 Cr | 17.30 | 3.10 | 0.48 | 17.90 | 17.30 | 8.29 | ||
3370.70 | 8,112 Cr | 19.63 | 9.43 | 3.49 | 42.11 | 52.41 | 25.64 | ||
| Median: 7 Co. | — | 1045.20 | 10,638 Cr | 41.69 | 9.43 | 0.48 | 19.57 | 24.16 | 15.10 |
